A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 1157
- Population
- ALL · 50 Years
- Duration
- 2018-09-25 to 2021-05-19
- Intervention
- 0.5 mg Conbercept Intravitreal Injection; 1.0 mg Conbercept Intravitreal Injection; 2.0 mg Aflibercept Intravitreal Injection
- Comparator
- Aflibercept
- Outcomes measured
- Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eye — Baseline to Week 36; Proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36 — Baseline to…; Proportion of subjects gaining ≥15 ETDRS BCVA letters from baseline to Week 36 — Baseline to Week 36; Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at…; Proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48 — Baseline to W…; Mean change from baseline in ETDRS BCVA letter score at Week 96 — Baseline and Week 96; Number of participants with adverse events as measure of safety and tolerability — Baseline to Week 96; Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible — Baseline to Week 96; Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible — Baseline to Week 96; Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible — Baseline to Wee…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.